Achieve Life Sciences, Inc. (ACHV) 10-Year Financial Performance & Capital Metrics

ACHV • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutAchieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.Show more

Revenue $0
EBITDA -$39M -43.7%
Net Income -$40M -33.6%
EPS (Diluted) -1.24 +17.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -409.51% +52.9%
ROIC -328.11%
Debt/Equity 0.48
Interest Coverage -17.92 -87.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 93 (top 7%)
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 61.8% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-58.9%

EPS CAGR

10Y-

5Y-

3Y-

TTM-22.12%

ROCE

10Y Avg-171.89%

5Y Avg-267.4%

3Y Avg-400.5%

Latest-256.11%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	18.16M	5.06M	0	0	0	0	0	0	0	0
Revenue Growth %	-0.33%	-0.72%	-1%	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	282K	282K	254K	255K	0	0	0	229K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	18.16M	5.06M	-282K	-282K	-254K	-255K	0	0	0	-229K
Gross Margin %	1%	1%	-	-	-	-	-	-	-	-
Gross Profit Growth %	-0.33%	-0.72%	-1.06%	0%	0.1%	-0%	1%	-	-	-
Operating Expenses+	36.91M	23.72M	6.63M	12.81M	16.53M	14.49M	33.09M	40.8M	27.25M	38.84M
OpEx % of Revenue	2.03%	4.69%	-	-	-	-	-	-	-	-
Selling, General & Admin	11.8M	8.93M	3.53M	6.95M	6.85M	7.61M	9.13M	10.72M	11.44M	16.25M
SG&A % of Revenue	0.65%	1.76%	-	-	-	-	-	-	-	-
Research & Development	25.11M	14.79M	3.1M	5.87M	9.67M	6.88M	23.97M	30.08M	15.81M	22.82M
R&D % of Revenue	1.38%	2.92%	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	165K	126K	133K	0	0	0	0	-229K
Operating Income+	-18.75M	-21.19M	-6.63M	-12.81M	-16.53M	-14.75M	-33.09M	-40.8M	-27.25M	-39.07M
Operating Margin %	-1.03%	-4.19%	-	-	-	-	-	-	-	-
Operating Income Growth %	0.36%	-0.13%	0.69%	-0.93%	-0.29%	0.11%	-1.24%	-0.23%	0.33%	-0.43%
EBITDA+	-18.51M	-21M	-6.35M	-12.53M	-16.27M	-14.49M	-32.84M	-40.56M	-27.02M	-38.84M
EBITDA Margin %	-1.02%	-4.15%	-	-	-	-	-	-	-	-
EBITDA Growth %	0.37%	-0.13%	0.7%	-0.97%	-0.3%	0.11%	-1.27%	-0.24%	0.33%	-0.44%
D&A (Non-Cash Add-back)	244K	188K	282K	282K	254K	255K	250K	236K	228K	229K
EBIT	-18.75M	-20.13M	-13.63M	-12.69M	-16.39M	-14.73M	-33.15M	-40.56M	-26.96M	-37.65M
Net Interest Income+	119K	0	0	0	170K	69K	17K	-1.59M	-2.03M	176K
Interest Income	119K	203K	21K	171K	170K	69K	17K	199K	825K	2.36M
Interest Expense	0	0	0	0	0	0	0	1.79M	2.85M	2.18M
Other Income/Expense	1.95M	-1.47M	-7M	126K	133K	20K	-58K	-1.55M	-2.56M	-758K
Pretax Income+	-16.8M	-20.13M	-13.63M	-12.69M	-16.39M	-14.73M	-33.15M	-42.35M	-29.82M	-39.83M
Pretax Margin %	-0.93%	-3.98%	-	-	-	-	-	-	-	-
Income Tax+	0	-1.06M	-3.05M	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	0.78%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-16.8M	-20.13M	-10.58M	-12.69M	-16.39M	-14.66M	-33.15M	-42.35M	-29.82M	-39.83M
Net Margin %	-0.93%	-3.98%	-	-	-	-	-	-	-	-
Net Income Growth %	0.36%	-0.2%	0.47%	-0.2%	-0.29%	0.11%	-1.26%	-0.28%	0.3%	-0.34%
Net Income (Continuing)	-16.8M	-20.13M	-10.58M	-12.69M	-16.39M	-14.73M	-33.15M	-42.35M	-29.82M	-39.83M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1413.63	-1474.98	-441.47	-72.29	-39.15	-5.39	-4.05	-3.95	-1.50	-1.24
EPS Growth %	0.56%	-0.04%	0.7%	0.84%	0.46%	0.86%	0.25%	0.02%	0.62%	0.17%
EPS (Basic)	-1413.63	-1478.66	-441.47	-72.29	-39.15	-5.39	-4.05	-3.95	-1.50	-1.24
Diluted Shares Outstanding	11.88K	13.65K	23.97K	175.51K	412.32K	2.72M	8.12M	10.59M	19.83M	32.07M
Basic Shares Outstanding	11.88K	13.61K	23.97K	175.51K	412.32K	2.72M	8.12M	10.59M	19.83M	32.07M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	57.57M	27.2M	5.91M	15.54M	17.33M	36.98M	44.59M	27.33M	16.98M	36.47M
Cash & Short-Term Investments	55.46M	25.73M	5.28M	14.65M	16.66M	35.85M	43.02M	24.72M	15.55M	34.34M
Cash Only	34.31M	15.23M	5.28M	9.52M	16.66M	35.85M	43.02M	24.72M	15.55M	12.73M
Short-Term Investments	20.88M	10.23M	0	5.09M	0	0	0	0	0	21.61M
Accounts Receivable	125K	510K	9K	7K	8K	0	153K	105K	111K	0
Days Sales Outstanding	2.51	36.77	-	-	-	-	-	-	-	-
Inventory	0	0	222K	-50K	0	0	0	0	0	0
Days Inventory Outstanding	-	-	287.34	-	-	-	-	-	-	-
Other Current Assets	0	0	222K	0	-8K	0	0	2.5M	1.32M	2.13M
Total Non-Current Assets+	639K	271K	3.98M	3.55M	3.74M	3.32M	2.92M	2.64M	2.39M	2.17M
Property, Plant & Equipment	639K	271K	59K	35K	386K	146K	64K	123K	79K	119K
Fixed Asset Turnover	28.42x	18.68x	-	-	-	-	-	-	-	-
Goodwill	1.03K	1.03K	1.03M	1.03M	1.03M	1.03M	1.03M	1.03M	1.03M	1.03M
Intangible Assets	2.98K	2.75K	2.53M	2.31M	2.09M	1.86M	1.64M	1.42M	1.2M	974K
Long-Term Investments	272K	272K	50K	50K	0	0	0	0	50K	0
Other Non-Current Assets	37K	13K	359K	168K	237K	279K	183K	66K	29K	39K
Total Assets+	58.21M	27.47M	9.89M	19.08M	21.08M	40.3M	47.52M	29.97M	19.37M	38.63M
Asset Turnover	0.31x	0.18x	-	-	-	-	-	-	-	-
Asset Growth %	0.03%	-0.53%	-0.64%	0.93%	0.1%	0.91%	0.18%	-0.37%	-0.35%	0.99%
Total Current Liabilities+	20.66M	8.46M	2.01M	3.27M	2.87M	2.94M	4.55M	21.6M	20.81M	6.68M
Accounts Payable	1.34M	2.12M	213K	144K	859K	332K	841K	1.66M	618K	1.95M
Days Payables Outstanding	-	-	275.69	186.38	1.23K	475.22	-	-	-	3.11K
Short-Term Debt	0	829K	27K	11K	0	0	0	16.07M	16.66M	0
Deferred Revenue (Current)	1000K	1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	12.96M	4.33M	1.29M	1.94M	1.12M	1.47M	1.94M	1.68M	2.84M	3.03M
Current Ratio	2.79x	3.22x	2.93x	4.75x	6.04x	12.60x	9.80x	1.27x	0.82x	5.46x
Quick Ratio	2.79x	3.22x	2.82x	4.77x	6.04x	12.60x	9.80x	1.27x	0.82x	5.46x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	105K	49K	240K	12K	159K	77K	14.92M	69K	6K	11.05M
Long-Term Debt	105K	0	0	12K	0	0	14.92M	0	0	9.84M
Capital Lease Obligations	105K	49K	0	12K	159K	77K	4K	69K	6K	66K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	-105K	0	0	-12K	0	0	0	0	0	1.15M
Total Liabilities	20.77M	8.5M	2.01M	3.28M	3.03M	3.01M	19.47M	21.67M	20.82M	17.73M
Total Debt+	157K	106K	27K	23K	362K	169K	14.99M	16.2M	16.73M	9.96M
Net Debt	-34.15M	-15.13M	-5.26M	-9.49M	-16.3M	-35.68M	-28.03M	-8.52M	1.19M	-2.77M
Debt / Equity	0.00x	0.01x	0.00x	0.00x	0.02x	0.00x	0.53x	1.95x	-	0.48x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-22.81x	-9.55x	-17.92x
Total Equity+	37.44M	18.97M	7.88M	15.8M	18.05M	37.29M	28.04M	8.3M	-1.45M	20.9M
Equity Growth %	0.1%	-0.49%	-0.58%	1.01%	0.14%	1.07%	-0.25%	-0.7%	-1.17%	15.43%
Book Value per Share	3150.19	1389.76	328.68	90.03	43.78	13.71	3.45	0.78	-0.07	0.65
Total Shareholders' Equity	37.44M	18.97M	7.88M	15.8M	18.05M	37.29M	28.04M	8.3M	-1.45M	20.9M
Common Stock	29K	29K	12K	18K	41K	76K	79K	87K	90K	103K
Retained Earnings	-176.81M	-196.94M	-12.69M	-25.38M	-45.7M	-60.43M	-93.59M	-135.94M	-165.75M	-205.58M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	2.63M	2.64M	5K	4K	4K	4K	4K	4K	4K	31K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.1M	-29.68M	-9.11M	-10.62M	-15.22M	-13.47M	-29.44M	-37.57M	-24.48M	-29.77M
Operating CF Margin %	-0.5%	-5.86%	-	-	-	-	-	-	-	-
Operating CF Growth %	0.47%	-2.26%	0.69%	-0.17%	-0.43%	0.11%	-1.18%	-0.28%	0.35%	-0.22%
Net Income	-16.8M	-20.13M	-10.58M	-12.69M	-16.39M	-14.73M	-33.15M	-42.35M	-29.82M	-39.83M
Depreciation & Amortization	244K	188K	282K	282K	254K	255K	250K	236K	228K	229K
Stock-Based Compensation	2.33M	1.65M	348K	854K	1.2M	1.29M	2.19M	3.27M	3.44M	5.33M
Deferred Taxes	-4.22M	-2.52M	-3.05M	0	0	-2.32M	0	0	0	0
Other Non-Cash Items	2.33M	1.85M	6.99M	1.49M	-3K	2.32M	41K	1.2M	2.45M	2.09M
Working Capital Changes	7.03M	-10.72M	-3.09M	928K	-273K	-285K	1.23M	79K	-778K	2.41M
Change in Receivables	5.66M	-464K	-9K	2K	-1K	0	-153K	48K	0	111K
Change in Inventory	-4.86M	-4.92M	-3.66M	285K	1K	0	0	0	0	0
Change in Payables	1.27M	778K	118K	-69K	715K	-527K	509K	799K	-1.04M	1.33M
Cash from Investing+	-2.08M	10.61M	12.65M	-5.13M	5.04M	-17K	0	0	-21K	-21.58M
Capital Expenditures	-371K	-46K	0	-46K	-53K	-17K	0	0	-21K	0
CapEx % of Revenue	0.02%	0.01%	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	12.65M	10K	5.09K	0	0	0	0	0
Cash from Financing+	17.59M	-2K	2M	19.76M	17.32M	32.68M	36.61M	19.32M	15.28M	48.53M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-38K	-2K	-5K	1.32M	4.2M	3.18M	338K	103K	7K	746K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.47M	-29.73M	-9.11M	-10.67M	-15.27M	-13.49M	-29.44M	-37.57M	-24.5M	-29.77M
FCF Margin %	-0.52%	-5.87%	-	-	-	-	-	-	-	-
FCF Growth %	0.46%	-2.14%	0.69%	-0.17%	-0.43%	0.12%	-1.18%	-0.28%	0.35%	-0.22%
FCF per Share	-796.97	-2178.43	-379.90	-60.79	-37.03	-4.96	-3.63	-3.55	-1.24	-0.93
FCF Conversion (FCF/Net Income)	0.54x	1.47x	0.86x	0.84x	0.93x	0.92x	0.89x	0.89x	0.82x	0.75x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-47%	-71.37%	-78.85%	-107.15%	-96.86%	-52.99%	-101.49%	-233.04%	-869.88%	-409.51%
Return on Invested Capital (ROIC)	-290.02%	-446.08%	-153.97%	-215.18%	-307.67%	-660.45%	-3073.75%	-	-	-328.11%
Gross Margin	100%	100%	-	-	-	-	-	-	-	-
Net Margin	-92.52%	-397.65%	-	-	-	-	-	-	-	-
Debt / Equity	0.00x	0.01x	0.00x	0.00x	0.02x	0.00x	0.53x	1.95x	-	0.48x
Interest Coverage	-	-	-	-	-	-	-	-22.81x	-9.55x	-17.92x
FCF Conversion	0.54x	1.47x	0.86x	0.84x	0.93x	0.92x	0.89x	0.89x	0.82x	0.75x
Revenue Growth	-33.03%	-72.13%	-100%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Achieve Life Sciences, Inc. (ACHV) grew revenue by 0.0% over the past year. Growth has been modest.

Achieve Life Sciences, Inc. (ACHV) reported a net loss of $52.3M for fiscal year 2024.

Dividend & Returns

Achieve Life Sciences, Inc. (ACHV) has a return on equity (ROE) of -409.5%. Negative ROE indicates the company is unprofitable.

Achieve Life Sciences, Inc. (ACHV) had negative free cash flow of $40.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Achieve Life Sciences, Inc. (ACHV) 10-Year Financial Performance & Capital Metrics

ACHV • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

Revenue $0
EBITDA -$39M -43.7%
Net Income -$40M -33.6%
EPS (Diluted) -1.24 +17.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -409.51% +52.9%
ROIC -328.11%
Debt/Equity 0.48
Interest Coverage -17.92 -87.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 93 (top 7%)
✓Trading near 52-week high

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 61.8% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-58.9%

EPS CAGR

10Y-

5Y-

3Y-

TTM-22.12%

ROCE

10Y Avg-171.89%

5Y Avg-267.4%

3Y Avg-400.5%

Latest-256.11%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	18.16M	5.06M	0	0	0	0	0	0	0	0
Revenue Growth %	-0.33%	-0.72%	-1%	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	282K	282K	254K	255K	0	0	0	229K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	18.16M	5.06M	-282K	-282K	-254K	-255K	0	0	0	-229K
Gross Margin %	1%	1%	-	-	-	-	-	-	-	-
Gross Profit Growth %	-0.33%	-0.72%	-1.06%	0%	0.1%	-0%	1%	-	-	-
Operating Expenses+	36.91M	23.72M	6.63M	12.81M	16.53M	14.49M	33.09M	40.8M	27.25M	38.84M
OpEx % of Revenue	2.03%	4.69%	-	-	-	-	-	-	-	-
Selling, General & Admin	11.8M	8.93M	3.53M	6.95M	6.85M	7.61M	9.13M	10.72M	11.44M	16.25M
SG&A % of Revenue	0.65%	1.76%	-	-	-	-	-	-	-	-
Research & Development	25.11M	14.79M	3.1M	5.87M	9.67M	6.88M	23.97M	30.08M	15.81M	22.82M
R&D % of Revenue	1.38%	2.92%	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	165K	126K	133K	0	0	0	0	-229K
Operating Income+	-18.75M	-21.19M	-6.63M	-12.81M	-16.53M	-14.75M	-33.09M	-40.8M	-27.25M	-39.07M
Operating Margin %	-1.03%	-4.19%	-	-	-	-	-	-	-	-
Operating Income Growth %	0.36%	-0.13%	0.69%	-0.93%	-0.29%	0.11%	-1.24%	-0.23%	0.33%	-0.43%
EBITDA+	-18.51M	-21M	-6.35M	-12.53M	-16.27M	-14.49M	-32.84M	-40.56M	-27.02M	-38.84M
EBITDA Margin %	-1.02%	-4.15%	-	-	-	-	-	-	-	-
EBITDA Growth %	0.37%	-0.13%	0.7%	-0.97%	-0.3%	0.11%	-1.27%	-0.24%	0.33%	-0.44%
D&A (Non-Cash Add-back)	244K	188K	282K	282K	254K	255K	250K	236K	228K	229K
EBIT	-18.75M	-20.13M	-13.63M	-12.69M	-16.39M	-14.73M	-33.15M	-40.56M	-26.96M	-37.65M
Net Interest Income+	119K	0	0	0	170K	69K	17K	-1.59M	-2.03M	176K
Interest Income	119K	203K	21K	171K	170K	69K	17K	199K	825K	2.36M
Interest Expense	0	0	0	0	0	0	0	1.79M	2.85M	2.18M
Other Income/Expense	1.95M	-1.47M	-7M	126K	133K	20K	-58K	-1.55M	-2.56M	-758K
Pretax Income+	-16.8M	-20.13M	-13.63M	-12.69M	-16.39M	-14.73M	-33.15M	-42.35M	-29.82M	-39.83M
Pretax Margin %	-0.93%	-3.98%	-	-	-	-	-	-	-	-
Income Tax+	0	-1.06M	-3.05M	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	0.78%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-16.8M	-20.13M	-10.58M	-12.69M	-16.39M	-14.66M	-33.15M	-42.35M	-29.82M	-39.83M
Net Margin %	-0.93%	-3.98%	-	-	-	-	-	-	-	-
Net Income Growth %	0.36%	-0.2%	0.47%	-0.2%	-0.29%	0.11%	-1.26%	-0.28%	0.3%	-0.34%
Net Income (Continuing)	-16.8M	-20.13M	-10.58M	-12.69M	-16.39M	-14.73M	-33.15M	-42.35M	-29.82M	-39.83M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1413.63	-1474.98	-441.47	-72.29	-39.15	-5.39	-4.05	-3.95	-1.50	-1.24
EPS Growth %	0.56%	-0.04%	0.7%	0.84%	0.46%	0.86%	0.25%	0.02%	0.62%	0.17%
EPS (Basic)	-1413.63	-1478.66	-441.47	-72.29	-39.15	-5.39	-4.05	-3.95	-1.50	-1.24
Diluted Shares Outstanding	11.88K	13.65K	23.97K	175.51K	412.32K	2.72M	8.12M	10.59M	19.83M	32.07M
Basic Shares Outstanding	11.88K	13.61K	23.97K	175.51K	412.32K	2.72M	8.12M	10.59M	19.83M	32.07M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	57.57M	27.2M	5.91M	15.54M	17.33M	36.98M	44.59M	27.33M	16.98M	36.47M
Cash & Short-Term Investments	55.46M	25.73M	5.28M	14.65M	16.66M	35.85M	43.02M	24.72M	15.55M	34.34M
Cash Only	34.31M	15.23M	5.28M	9.52M	16.66M	35.85M	43.02M	24.72M	15.55M	12.73M
Short-Term Investments	20.88M	10.23M	0	5.09M	0	0	0	0	0	21.61M
Accounts Receivable	125K	510K	9K	7K	8K	0	153K	105K	111K	0
Days Sales Outstanding	2.51	36.77	-	-	-	-	-	-	-	-
Inventory	0	0	222K	-50K	0	0	0	0	0	0
Days Inventory Outstanding	-	-	287.34	-	-	-	-	-	-	-
Other Current Assets	0	0	222K	0	-8K	0	0	2.5M	1.32M	2.13M
Total Non-Current Assets+	639K	271K	3.98M	3.55M	3.74M	3.32M	2.92M	2.64M	2.39M	2.17M
Property, Plant & Equipment	639K	271K	59K	35K	386K	146K	64K	123K	79K	119K
Fixed Asset Turnover	28.42x	18.68x	-	-	-	-	-	-	-	-
Goodwill	1.03K	1.03K	1.03M	1.03M	1.03M	1.03M	1.03M	1.03M	1.03M	1.03M
Intangible Assets	2.98K	2.75K	2.53M	2.31M	2.09M	1.86M	1.64M	1.42M	1.2M	974K
Long-Term Investments	272K	272K	50K	50K	0	0	0	0	50K	0
Other Non-Current Assets	37K	13K	359K	168K	237K	279K	183K	66K	29K	39K
Total Assets+	58.21M	27.47M	9.89M	19.08M	21.08M	40.3M	47.52M	29.97M	19.37M	38.63M
Asset Turnover	0.31x	0.18x	-	-	-	-	-	-	-	-
Asset Growth %	0.03%	-0.53%	-0.64%	0.93%	0.1%	0.91%	0.18%	-0.37%	-0.35%	0.99%
Total Current Liabilities+	20.66M	8.46M	2.01M	3.27M	2.87M	2.94M	4.55M	21.6M	20.81M	6.68M
Accounts Payable	1.34M	2.12M	213K	144K	859K	332K	841K	1.66M	618K	1.95M
Days Payables Outstanding	-	-	275.69	186.38	1.23K	475.22	-	-	-	3.11K
Short-Term Debt	0	829K	27K	11K	0	0	0	16.07M	16.66M	0
Deferred Revenue (Current)	1000K	1000K	0	0	0	0	0	0	0	0
Other Current Liabilities	12.96M	4.33M	1.29M	1.94M	1.12M	1.47M	1.94M	1.68M	2.84M	3.03M
Current Ratio	2.79x	3.22x	2.93x	4.75x	6.04x	12.60x	9.80x	1.27x	0.82x	5.46x
Quick Ratio	2.79x	3.22x	2.82x	4.77x	6.04x	12.60x	9.80x	1.27x	0.82x	5.46x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	105K	49K	240K	12K	159K	77K	14.92M	69K	6K	11.05M
Long-Term Debt	105K	0	0	12K	0	0	14.92M	0	0	9.84M
Capital Lease Obligations	105K	49K	0	12K	159K	77K	4K	69K	6K	66K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	-105K	0	0	-12K	0	0	0	0	0	1.15M
Total Liabilities	20.77M	8.5M	2.01M	3.28M	3.03M	3.01M	19.47M	21.67M	20.82M	17.73M
Total Debt+	157K	106K	27K	23K	362K	169K	14.99M	16.2M	16.73M	9.96M
Net Debt	-34.15M	-15.13M	-5.26M	-9.49M	-16.3M	-35.68M	-28.03M	-8.52M	1.19M	-2.77M
Debt / Equity	0.00x	0.01x	0.00x	0.00x	0.02x	0.00x	0.53x	1.95x	-	0.48x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-22.81x	-9.55x	-17.92x
Total Equity+	37.44M	18.97M	7.88M	15.8M	18.05M	37.29M	28.04M	8.3M	-1.45M	20.9M
Equity Growth %	0.1%	-0.49%	-0.58%	1.01%	0.14%	1.07%	-0.25%	-0.7%	-1.17%	15.43%
Book Value per Share	3150.19	1389.76	328.68	90.03	43.78	13.71	3.45	0.78	-0.07	0.65
Total Shareholders' Equity	37.44M	18.97M	7.88M	15.8M	18.05M	37.29M	28.04M	8.3M	-1.45M	20.9M
Common Stock	29K	29K	12K	18K	41K	76K	79K	87K	90K	103K
Retained Earnings	-176.81M	-196.94M	-12.69M	-25.38M	-45.7M	-60.43M	-93.59M	-135.94M	-165.75M	-205.58M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	2.63M	2.64M	5K	4K	4K	4K	4K	4K	4K	31K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.1M	-29.68M	-9.11M	-10.62M	-15.22M	-13.47M	-29.44M	-37.57M	-24.48M	-29.77M
Operating CF Margin %	-0.5%	-5.86%	-	-	-	-	-	-	-	-
Operating CF Growth %	0.47%	-2.26%	0.69%	-0.17%	-0.43%	0.11%	-1.18%	-0.28%	0.35%	-0.22%
Net Income	-16.8M	-20.13M	-10.58M	-12.69M	-16.39M	-14.73M	-33.15M	-42.35M	-29.82M	-39.83M
Depreciation & Amortization	244K	188K	282K	282K	254K	255K	250K	236K	228K	229K
Stock-Based Compensation	2.33M	1.65M	348K	854K	1.2M	1.29M	2.19M	3.27M	3.44M	5.33M
Deferred Taxes	-4.22M	-2.52M	-3.05M	0	0	-2.32M	0	0	0	0
Other Non-Cash Items	2.33M	1.85M	6.99M	1.49M	-3K	2.32M	41K	1.2M	2.45M	2.09M
Working Capital Changes	7.03M	-10.72M	-3.09M	928K	-273K	-285K	1.23M	79K	-778K	2.41M
Change in Receivables	5.66M	-464K	-9K	2K	-1K	0	-153K	48K	0	111K
Change in Inventory	-4.86M	-4.92M	-3.66M	285K	1K	0	0	0	0	0
Change in Payables	1.27M	778K	118K	-69K	715K	-527K	509K	799K	-1.04M	1.33M
Cash from Investing+	-2.08M	10.61M	12.65M	-5.13M	5.04M	-17K	0	0	-21K	-21.58M
Capital Expenditures	-371K	-46K	0	-46K	-53K	-17K	0	0	-21K	0
CapEx % of Revenue	0.02%	0.01%	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	12.65M	10K	5.09K	0	0	0	0	0
Cash from Financing+	17.59M	-2K	2M	19.76M	17.32M	32.68M	36.61M	19.32M	15.28M	48.53M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-38K	-2K	-5K	1.32M	4.2M	3.18M	338K	103K	7K	746K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.47M	-29.73M	-9.11M	-10.67M	-15.27M	-13.49M	-29.44M	-37.57M	-24.5M	-29.77M
FCF Margin %	-0.52%	-5.87%	-	-	-	-	-	-	-	-
FCF Growth %	0.46%	-2.14%	0.69%	-0.17%	-0.43%	0.12%	-1.18%	-0.28%	0.35%	-0.22%
FCF per Share	-796.97	-2178.43	-379.90	-60.79	-37.03	-4.96	-3.63	-3.55	-1.24	-0.93
FCF Conversion (FCF/Net Income)	0.54x	1.47x	0.86x	0.84x	0.93x	0.92x	0.89x	0.89x	0.82x	0.75x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-47%	-71.37%	-78.85%	-107.15%	-96.86%	-52.99%	-101.49%	-233.04%	-869.88%	-409.51%
Return on Invested Capital (ROIC)	-290.02%	-446.08%	-153.97%	-215.18%	-307.67%	-660.45%	-3073.75%	-	-	-328.11%
Gross Margin	100%	100%	-	-	-	-	-	-	-	-
Net Margin	-92.52%	-397.65%	-	-	-	-	-	-	-	-
Debt / Equity	0.00x	0.01x	0.00x	0.00x	0.02x	0.00x	0.53x	1.95x	-	0.48x
Interest Coverage	-	-	-	-	-	-	-	-22.81x	-9.55x	-17.92x
FCF Conversion	0.54x	1.47x	0.86x	0.84x	0.93x	0.92x	0.89x	0.89x	0.82x	0.75x
Revenue Growth	-33.03%	-72.13%	-100%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Achieve Life Sciences, Inc. (ACHV) grew revenue by 0.0% over the past year. Growth has been modest.

Achieve Life Sciences, Inc. (ACHV) reported a net loss of $52.3M for fiscal year 2024.

Dividend & Returns

Achieve Life Sciences, Inc. (ACHV) has a return on equity (ROE) of -409.5%. Negative ROE indicates the company is unprofitable.

Achieve Life Sciences, Inc. (ACHV) had negative free cash flow of $40.7M in fiscal year 2024, likely due to heavy capital investments.